Targeting VSTM-1 using anti-VSTM-1 agonist MAb reduces COPD pathology in vivo

Jan. 22, 2024

Researchers from Nextcure Inc. have reported the development and preclinical characterization of a novel agonist monoclonal antibody (MAb) against V-set and transmembrane domain containing 1 (VSTM-1).

BioWorld Science Conferences Respiratory Monoclonal antibody

Today's news in brief

BioWorld

BioWorld briefs for April 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 3, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Illustration of female reproductive system with polycystic ovary

First atlas of the endometrium with polycystic ovary syndrome

BioWorld Science

Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial dysfunction in women who have hormonal...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...